ProjektRD.06.SPR.118161 – A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of…

Grunddaten

Akronym:

RD.06.SPR.118161

Titel:

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis

Laufzeit:

08.02.2021 bis 01.02.2022

Abstract / Kurz- beschreibung:

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with
Moderate-to-Severe Atopic Dermatitis

Schlüsselwörter:

Atopische Dermatitis

atopic dermatitis